My primary area of interest is in the biology, management, and late effects of childhood brain and spinal cord tumors. I participate in the Children's Oncology Group (COG), a North American multi-institutional collaboration in treatment of childhood cancer and clinical and supportive care trials. I also participate in the Canadian Pediatric Brain Tumour Consortium, where we collaborate nationally in conducting research in pediatric brain tumors. Locally, I participate in research at the clinical level where treatments, quality of life, late effects of treatments, and other clinically-related questions are evaluated.
Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation Journal of Neuro-Oncology Sylvia Cheng and John-Paul Kilday and Normand Laperriere and Laura Janzen and James Drake and Eric Bouffet and Ute Bartels DOI: 10.1007/s11060-015-2029-1 01/2016
Do we need a formalized humanism and professionalism curriculum in pediatric hematology and oncology training? Pediatric Blood & Cancer Sylvia Cheng and Meera Rayar and Angela Punnett DOI: 10.1002/pbc.25638 07/2015
Improving the Curriculum in the Pediatric Hematology and Oncology (PHO) Residency Program Paediatric Blood and Cancer 06/2015
Long term outcomes in children with intracranial germinoma: a single institution experience from 2000-2013 Neuro-Oncology 06/2014
Early deaths in pediatric acute leukemia: a population-based study Paediatric Blood and Cancer 09/2013
Pathological findings of subependymal giant cell astrocytoma following treatment with mammalian target of rapamycin (mTOR) inhibitor Rapamycin Paediatric Blood and Cancer 06/2013
Completing a scholarly project during paediatric residency: motivators, barriers, and enablers Paediatric and Child Health 06/2013
Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia Journal of Clinical Epidemiology Lillian Sung and Shabbir M. Alibhai and Marie-Chantal Ethier and Oliver Teuffel and Sylvia Cheng and David Fisman and Dean A. Regier DOI: 10.1016/j.jclinepi.2011.11.008 06/2012
Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients Supportive Care in Cancer O. Teuffel and S. Cheng and M. C. Ethier and C. Diorio and J. Martino and C. Mayo and R. Wing and L. Sung and S. M. H. Alibhai DOI: 10.1007/s00520-012-1397-8 02/2012
Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia British Journal of Cancer S Cheng and O Teuffel and M C Ethier and C Diorio and J Martino and C Mayo and D Regier and R Wing and S M H Alibhai and L Sung DOI: 10.1038/bjc.2011.213 06/2011
Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia Paediatric and Child Health 06/2011
Delayed Diagnosis of CNS Tumors in Children Central nervous system (CNS) tumors in chidlren account for a quarter of all cancers in children but diagnosis is often delayed as symptoms are not specific and more benign conditions are more common. Furthermore, the diagnosis of CNS tumors necessittes a comprehensive clinical history and complete examination in addition to advanced imaging. Delay in diagnosis of CNS tumors in children can be devastating for families and clinicians and time to diagnosis is critical in an effort to provide the best surgical and non-surgical care. Despite ample research and improvements in quality and access to diagnostic imaging, time to diagnosis in children has been less than optimal with reports of 5-8 months from time of symptom presentation to diagnosis. Therefore, we hope to retrospectively evaluate the time to diagnosis of CNS tumors in children in British Columbia with the aim of developing an algorithm and educational tools to aid health care providers in management prospectively.
International DIPG Registry Diffuse Intrinsic Pontine Glioma (DIPG) is a devastating brainstem tumor that occurs in young children. Despite attempts of novel therapeutics or conventional radiation therapy, the prognosis remains dismal. Therefore, the primary aim of the DIPG Registry is to collaborate with all pediatric centers internationally to form a clinical, radiological, and tissue repository for the basis of a platform to provide collaborative efforts and research to occur in an extremely rare disease.
Headstart 4 Earlier generations of multi-center "Baby" protocols have demonstrated the feasibility of chemotherapy-only strategies for young children with newly diagnosed malignant brain tumors. The disease-free survivals attained with these regimens, however, remained worse compared to regimens that include radiation therapy. The previous generations of Headstart studies (1-3) demonstrated favourable outcomes for certain patient groups. Recent genomic advances in RNA and DNA profiling have identified four molecular subgroups of medulloblastoma that confer prognosis. However, all the analyses to date have been conducted on patients where the majority received radiation therapy. Therefore, the primary aims of Headstart 4 is to determine prospectively, in a randomized fashion, whether there is a difference in event-free and overall survival in those who receive a dose-intensive tandem consolidation vs. single consolidation in high risk patients with medulloblastoma and embryonal CNS tumors based on prospective molecular risk stratification.
Human DNA testing could improve outcomes for patients with COVID-19.
That’s the key idea put forth in preliminary research posted this month to bioRxiv that highlights the potential benefits of testing COVID-19 patients for genetic variants of ACE2—the protein identified as the point-of-entry for the SARS-COV-2 virus into human cells.
Congratulations to the BC Children's and BC Women's investigators who were awarded funding through the highly competitive Canadian Institutes of Health Research (CIHR) Project Grant Fall 2019 competition.
A new study suggests that specialized immune cells that dampen inflammation and help repair the gut could be used as a potential therapy for children dealing with the painful symptoms of inflammatory bowel disease.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.